Category: 1589082-06-3

Fell, Jay B. et al. published their research in Journal of Medicinal Chemistry in 2020 | CAS: 1589082-06-3

(S)-tert-Butyl 3-(cyanomethyl)piperazine-1-carboxylate (cas: 1589082-06-3) belongs to piperazine derivatives. Piperazine is a fairly basic compound and is an amine solvent. Piperazine is formed as a co-product in the ammoniation of 1,2-dichloroethane or ethanolamine. These are the only routes to the chemical used commercially.Synthetic Route of C11H19N3O2

Identification of the Clinical Development Candidate MRTX849, a Covalent KRASG12C Inhibitor for the Treatment of Cancer was written by Fell, Jay B.;Fischer, John P.;Baer, Brian R.;Blake, James F.;Bouhana, Karyn;Briere, David M.;Brown, Karin D.;Burgess, Laurence E.;Burns, Aaron C.;Burkard, Michael R.;Chiang, Harrah;Chicarelli, Mark J.;Cook, Adam W.;Gaudino, John J.;Hallin, Jill;Hanson, Lauren;Hartley, Dylan P.;Hicken, Erik J.;Hingorani, Gary P.;Hinklin, Ronald J.;Mejia, Macedonio J.;Olson, Peter;Otten, Jennifer N.;Rhodes, Susan P.;Rodriguez, Martha E.;Savechenkov, Pavel;Smith, Darin J.;Sudhakar, Niranjan;Sullivan, Francis X.;Tang, Tony P.;Vigers, Guy P.;Wollenberg, Lance;Christensen, James G.;Marx, Matthew A.. And the article was included in Journal of Medicinal Chemistry in 2020.Synthetic Route of C11H19N3O2 This article mentions the following:

Capping off an era marred by drug development failures and punctuated by waning interest and presumed intractability toward direct targeting of KRAS, new technologies and strategies are aiding in the target’s resurgence. As previously reported, the tetrahydropyridopyrimidines were identified as irreversible covalent inhibitors of KRASG12C that bind in the switch-II pocket of KRAS and make a covalent bond to cysteine 12. Using structure-based drug design in conjunction with a focused in vitro absorption, distribution, metabolism and excretion screening approach, analogs were synthesized to increase the potency and reduce metabolic liabilities of this series. The discovery of the clin. development candidate MRTX849(I)as a potent, selective covalent inhibitor of KRASG12C is described. In the experiment, the researchers used many compounds, for example, (S)-tert-Butyl 3-(cyanomethyl)piperazine-1-carboxylate (cas: 1589082-06-3Synthetic Route of C11H19N3O2).

(S)-tert-Butyl 3-(cyanomethyl)piperazine-1-carboxylate (cas: 1589082-06-3) belongs to piperazine derivatives. Piperazine is a fairly basic compound and is an amine solvent. Piperazine is formed as a co-product in the ammoniation of 1,2-dichloroethane or ethanolamine. These are the only routes to the chemical used commercially.Synthetic Route of C11H19N3O2

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

Sep 2021 News Analyzing the synthesis route of (S)-tert-Butyl 3-(cyanomethyl)piperazine-1-carboxylate

The synthetic route of 1589082-06-3 has been constantly updated, and we look forward to future research findings.

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1589082-06-3,(S)-tert-Butyl 3-(cyanomethyl)piperazine-1-carboxylate,as a common compound, the synthetic route is as follows.

A reaction mixture of tert-butyl (3S)-3-(cyanomethyl)piperazine-1-carboxylate (850 mg, 3.77 mmol) and HCl/dioxane (4 M, 20 mL) was stirred at 15° C. for 1 hour. Upon completion, the solvent was removed under vacuum to give 2-[(2S)-piperazin-2-yl]acetonitrile (740 mg, 3.74 mmol, 99.0% yield, 2HCl) as a white solid. 1H NMR (400 MHz, METHANOL-d 4) delta=4.04-3.90 (m, 1H), 3.81-3.70 (m, 2H), 3.69-3.61 (m, 2H), 3.53-3.36 (m, 2H), 3.13 (d, J=6.4 Hz, 2H)., 1589082-06-3

The synthetic route of 1589082-06-3 has been constantly updated, and we look forward to future research findings.

Reference：
Patent; Mirati Therapeutics, Inc.; Array BioPharma Inc.; Blake, James F.; Burgess, Laurence E.; Chicarelli, Mark Joseph; Christensen, James Gail; Cook, Adam; Fell, Jay Bradford; Fischer, John P.; Marx, Matthew Arnold; Mejia, Macedonio J.; Savechenkov, Pavel; Vigers, Guy P.A.; Smith, Christopher Ronald; Rodriguez, Martha E.; US2019/144444; (2019); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics